Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women
This study is currently recruiting patients.
Sponsored by: | FDA Office of Orphan Products Development Charles R. Drew University of Medicine and Science
|
---|---|
Information provided by: | FDA Office of Orphan Products Development |
Purpose
OBJECTIVES: I. Determine whether physiologic testosterone replacement can increase fat-free mass, therefore contributing to weight maintenance, improved muscle function, and quality of life in HIV-infected women. II. Examine the mechanism of testosterone-induced increase in fat-free mass.
Condition | Treatment or Intervention | Phase |
---|---|---|
HIV Infections Cachexia |
Drug: testosterone |
Phase II |
MedlinePlus related topics: AIDS
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study
Expected Total Enrollment: 56
Study start: April 1997
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are randomized to one of three arms. Arm I: Patients receive two placebo transdermal patches applied twice a week (every 3-4 days). Arm II: Patients receive one testosterone transdermal patch and one placebo transdermal patch applied twice a week (every 3-4 days). Arm III: Patients receive two testosterone transdermal patches applied twice a week (every 3-4 days). Patients receive 12 weeks of treatment in the absence of adverse reaction or health deterioration. Patients are followed on day 1, every 2 weeks during treatment, and at the end of the recovery period. Quality of life is assessed before treatment begins and at weeks 6 and 12.
Eligibility
Ages Eligible for Study: 18 Years - 50 Years, Genders Eligible for Study: Female
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |